IL274083A - Diagnostic methods for anti-angiogenic agent therapy - Google Patents

Diagnostic methods for anti-angiogenic agent therapy

Info

Publication number
IL274083A
IL274083A IL274083A IL27408320A IL274083A IL 274083 A IL274083 A IL 274083A IL 274083 A IL274083 A IL 274083A IL 27408320 A IL27408320 A IL 27408320A IL 274083 A IL274083 A IL 274083A
Authority
IL
Israel
Prior art keywords
diagnostic methods
angiogenic agent
agent therapy
therapy
angiogenic
Prior art date
Application number
IL274083A
Other languages
Hebrew (he)
Inventor
Breitbart Eyal
Mendel Itzhak
Original Assignee
Breitbart Eyal
Mendel Itzhak
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breitbart Eyal, Mendel Itzhak, Vascular Biogenics Ltd filed Critical Breitbart Eyal
Publication of IL274083A publication Critical patent/IL274083A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL274083A 2017-10-20 2020-04-20 Diagnostic methods for anti-angiogenic agent therapy IL274083A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575193P 2017-10-20 2017-10-20
US201862722671P 2018-08-24 2018-08-24
PCT/IB2018/058218 WO2019077593A1 (en) 2017-10-20 2018-10-22 Diagnostic methods for anti-angiogenic agent therapy

Publications (1)

Publication Number Publication Date
IL274083A true IL274083A (en) 2020-06-30

Family

ID=64564920

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274083A IL274083A (en) 2017-10-20 2020-04-20 Diagnostic methods for anti-angiogenic agent therapy

Country Status (6)

Country Link
US (1) US20210322574A1 (en)
EP (1) EP3697451A1 (en)
JP (1) JP2021500355A (en)
CN (1) CN111356480A (en)
IL (1) IL274083A (en)
WO (1) WO2019077593A1 (en)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
SI1325932T1 (en) 1997-04-07 2005-08-31 Genentech Inc
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
EP2277887A3 (en) * 2001-10-19 2011-02-16 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
ES2362931T3 (en) 2002-03-04 2011-07-15 Imclone Llc SPECIFIC HUMAN ANTIBODIES AGAINST KDR AND USES OF THE SAME.
CN102397542B (en) 2004-11-18 2014-05-07 英克隆有限责任公司 Antibodies against vascular endothelial growth factor receptor-1
BRPI0820298A8 (en) 2007-11-09 2018-05-08 Affitech Res As anti-vegf antibody compositions and methods
AU2011204405B2 (en) * 2010-01-05 2015-06-18 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
SG10201500048SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
EA022941B1 (en) 2010-10-18 2016-03-31 Тотал Ресерч Энд Текнолоджи Фелюи Process to increase the melt flow index of an expandable vinyl aromatic polymer
LT2908865T (en) * 2012-10-17 2019-01-10 Vascular Biogenics Ltd. Adenovirus expressing a fas-chimera and use thereof in cancer treatment methods
WO2014118643A2 (en) * 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent

Also Published As

Publication number Publication date
CN111356480A (en) 2020-06-30
EP3697451A1 (en) 2020-08-26
JP2021500355A (en) 2021-01-07
US20210322574A1 (en) 2021-10-21
WO2019077593A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
ZA201804141B (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
HK1248773A1 (en) Therapeutic and diagnostic methods for cancer
HK1250376A1 (en) Therapeutic and diagnostic methods for cancer
IL250685A0 (en) Cytotoxicity-inducing therapeutic agent
EP3288455C0 (en) Diagnostic methods
SG10202006688RA (en) Bicyclic compounds for diagnosis and therapy
GB201513540D0 (en) Therapeutic agents
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
GB201509893D0 (en) Therapeutic agents
IL263205A (en) Methods for making ultrasound contrast agents
GB201517263D0 (en) Therapeutic agents
HK1251022A1 (en) Diagnostic methods
PL3481933T3 (en) Anti-greying agent
GB201509885D0 (en) Therapeutic agents
GB201509888D0 (en) Therapeutic agents
GB2556021B (en) Medical apparatus
GB201615753D0 (en) Diagnostic method
GB201513299D0 (en) Therapeutic agents
GB201620641D0 (en) Agent
SG11201700059WA (en) Therapeutic agent for keratoconjunctive disorder
EP3535421C0 (en) Diagnostic methods
IL274083A (en) Diagnostic methods for anti-angiogenic agent therapy
PL3413712T3 (en) Disinfection agent
GB201517264D0 (en) Therapeutic agents
GB201702921D0 (en) Therapeutic agent